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INTRODUCTION
The role of high-dose therapy (HDT) with autologous
hematopoietic cell transplantation for patients with relapsed
follicular low-grade lymphoma (FLGL) has been examined
by a number of studies [1-9]. Although these studies have
yielded considerable information regarding survival out-
come, few consistent prognostic variables that correlate with
outcome have been identiﬁed, and whether there is an opti-
mal preparative regimen has not been established.
In this study we describe the results of our single-
institution 10-year experience with HDT and purged autol-
ogous hematopoietic cell transplantation in 92 patients with
follicular lymphoma who were not in ﬁrst remission. Within
this group were 49 patients with relapsed FLGL. We have
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ABSTRACT
A retrospective analysis was performed to investigate the outcome of high-dose therapy (HDT) and autologous
hematopoietic cell transplantation in patients with follicular lymphomas beyond first remission. Ninety-two patients
with primary induction failure or relapsed follicular low-grade lymphoma (FLGL), follicular large cell lymphoma
(FLCL), and transformed follicular lymphoma (TFL) were treated with myeloablative therapy consisting of etoposide
(60 mg/kg), cyclophosphamide (100 mg/kg), and either carmustine (BCNU;15 mg/kg) or fractionated total body irra-
diation (FTBI; 1200 cGy) followed by transplantation of purged autologous bone marrow or peripheral blood
hematopoietic cells. For the 49 patients with relapsed FLGL, the median age was 49 years and the median interval
from diagnosis to HDT was 30 months. The 4-year estimate of overall survival (OS) was 60% (95% confidence inter-
val [CI], 45%-75%) and of disease-free survival (DFS) was 44% (95% CI, 29%-59%). Treatment with the FTBI-
containing HDT regimen was associated with significantly longer DFS (P = .04) and OS (P = .04) in our multivariate
analysis. OS was also significantly longer among those treated with 3 or fewer chemotherapy regimens. For the
26 FLCL patients, the median age was 51 years and in 31% the indication for HDT was primary induction failure.
For FLCL patients, the 4-year estimate of OS was 58% (95% CI, 37%-79%) and of DFS was 51% (95% CI, 30%-
72%). Among the 17 patients with TFL, 13 (76%) transformed at first relapse, and only 6 patients (35%) achieved
complete remission with salvage therapy prior to HDT. For TFL patients, the 4-year estimate of OS was 50% (95%
CI, 24%-76%) and of DFS 49% (95% CI, 20%-78%). There were 3 occurrences of myelodysplasia (1 after treatment
with TBI, 2 after BCNU treatment), yielding an estimated incidence of 7% (95% CI, 0%-16%) at 56 months. This
analysis shows that relapsed FLGL patients treated with 3 or fewer different chemotherapy regimens show inferior
survival. The HDT regimen containing FTBI appears to be superior to the BCNU-based regimen for relapsed
FLGL, although longer follow-up is needed to evaluate late effects. Lastly, patients with TFL or induction failure and
relapsed FLCL can achieve survival outcome comparable to those observed with the indolent follicular lymphomas.
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also analyzed outcome for 26 patients with induction failure
or relapsed follicular large cell lymphoma (FLCL) and
17 patients with transformed follicular lymphoma (TFL).
Our aim was to investigate outcome and to identify poten-
tial prognostic factors.
PATIENTS AND METHODS
Patients
A computerized database query was used to identify
94 consecutive patients treated with HDT who were regis-
tered with a histologic diagnosis of follicular lymphoma. This
number did not include FLGL patients in first remission
treated with HDT under a separate research protocol that
concurrently accrued patients during the active study period.
In addition, excluded from this analysis were 2 patients who had
discordant lymphomas with synchronous diffuse large cell lym-
phoma at distant sites. A retrospective review of the clinical data
was performed for the remaining 92 patients. All patients were
treated with HDT and autologous hematopoietic cell transplan-
tation between March 9, 1988, and March 24, 1999. The
median follow-up among all surviving patients for the entire
group at the time of this analysis was 56 months (range, 8-134
months). The initial diagnostic biopsy specimens from all
patients were available for review and the histologic characteris-
tics are summarized in Table 1. Forty-nine patients were cate-
gorized as having FLGL following a diagnosis of follicular small
cleaved cell or follicular mixed NHL as deﬁned by the Interna-
tional Working Formulation [10]. Patients with a mixed archi-
tectural pattern were also considered to have FLGL if the cell
type was small cleaved cell or mixed small cleaved and large cell
and any follicular component was present. Twenty-six patients
were classiﬁed as having FLCL as previously described [11].
Seventeen patients had histologically proven TFL; in 12 of
these patients, the disease had undergone conversion from
FLGL to a diffuse large cell lymphoma. Five additional patients
with an original diagnosis of FLCL transformed to diffuse large
cell lymphoma were included in this analysis as TFL.
All patients were treated following written informed
consent under a research protocol approved by the Stanford
University Medical Center Administrative Panel on Medical
Human Subjects. Inclusion criteria required relapsed disease
following attainment of remission with conventional ther-
apy, failure to achieve a complete remission following initial
therapy, or progressive disease during initial therapy.
Although strict definitions of minimal disease status were
not implemented, demonstration of sensitivity to chemo-
therapy prior to HDT was required for all patients. Exclu-
sion criteria included abnormal hepatic function, prior
hematopoietic cell transplantation procedures, and severe
psychological disorders or serious comorbid conditions.
Collection and Processing of Hematopoietic Cells
Bone marrow was harvested from the posterior iliac
crests while the patient was under general anesthesia [12].
Peripheral blood hematopoietic cells were collected via
apheresis following “mobilization” with cyclophosphamide 4
gm/m2, and granulocyte colony-stimulating factor (G-CSF;
10mg/kg per day with the dose rounded to the nearest vial
size). With the exception of the ﬁrst 3, for all patients the
autograft was density fractionated on a Percoll gradient and
“purged” with monoclonal antibodies and rabbit comple-
ment prior to cryopreservation as previously described [13].
A panel of monoclonal antibodies directed against B
lymphocytes was used and included J9 (anti-CD9), 4-35
(anti-CD10), J149 (anti-CD19), and 1F5 (anti-CD20)
(Chromaprobe Inc, Mountain View, CA).
High-Dose Therapy and Autologous Hematopoietic
Cell Transplantation
Patients were treated with a myeloablative HDT regi-
men consisting of fractionated total body irradiation (FTBI)
in 10 equal fractions to a total dose of 1200 cGy, etoposide
60 mg/kg, and cyclophosphamide 100 mg/kg as previously
described [14]. Carmustine (BCNU) at a dose of 15 mg/kg,
to a maximum of 550 mg/m2, was substituted for FTBI if
the patient had received prior radiotherapy to the chest or
pelvis, if excessive morbidity with FTBI was anticipated on
the basis of higher age (over 60 years) or poor Karnofsky’s
performance status (<70%), or if patients refused to undergo
total body irradiation [14]. During the initial period of
accrual, patients were received transplants of monoclonal
antibody–purged autologous bone marrow (n = 36). Subse-
quent to September 29, 1993, all patients (n = 56) received
autologous peripheral blood hematopoietic cells with the
exception of 2 patients who failed to “mobilize” adequately
with chemotherapy and G-CSF and thus received trans-
plants of “purged” autologous bone marrow [15]. Posttrans-
plantation supportive care was delivered according to standard
institutional practice as previously described [14].
Statistical Analysis
Outcome was analyzed with respect to overall survival
(OS) and disease-free survival (DFS). OS time was deﬁned as
time from HDT to death from any cause or until last follow-
up evaluation for patients who were alive. DFS was deﬁned
as time from HDT to relapse or progression of disease from
best remission, death from any cause, or until last follow-up
if none of these events had occurred. For the entire patient
group and the subset of patients with FLGL, Cox propor-
tional hazards univariate and multivariate regression models
for both categorical and continuous variables were used to
identify predictors of OS and DFS [16]. Signiﬁcance (P ≤ .05)
was determined from the Wald χ2 test. The Kaplan-Meier
method was used to estimate the actuarial OS and DFS, and
Table 1. Histologic Subgroups for All Patients
No. of Patients
Follicular low-grade lymphoma 49
Follicular small 15
Follicular mixed 22
Mixed architecture follicular small 3
Mixed architecture follicular mixed 9
Follicular large cell lymphoma 26
Follicular large 14
Mixed architecture follicular large 12
Transformed follicular lymphoma 17
From follicular small/mixed 12
From follicular large 5
Total 92
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differences between the patient groups were assessed with
the log-rank test [17,18]. Differences in the median observa-
tions and proportions of patient characteristic variables
between the groups treated with the FTBI and the non-
FTBI regimen were determined with the Wilcoxon rank sum
test and the Fisher exact test, respectively [19].
RESULTS
Patient Characteristics
The patient characteristics for the 49 patients with FLGL,
the 26 patients with FLCL, and the 17 patients with TFL are
summarized in Table 2. The median age at the time of HDT
for the group as a whole was 48 years (range, 28-68 years).
The median time from diagnosis to HDT for the group as a
whole was 30 months (range, 7-301 months). At initial diag-
nosis most patients with FLGL had stage IV disease, 22 of
whom (45%) had nonmarrow extranodal involvement that
included skin (n = 4), central nervous system (n = 2), gastroin-
testinal tract (n = 6), and pleural ﬂuid (n = 4) at some point
prior to HDT. Only a few patients from all 3 groups had
either B symptoms or a bulky mass prior to HDT.
For the 17 TFL patients, transformation was histologi-
cally documented at ﬁrst relapse in 13 (76%), and at second
relapse in the remaining 4 patients. At the time of transfor-
mation, 10 patients (59%) had stage IV disease. The median
time interval from diagnosis to histologic transformation was
35 months (range, 7-149 months). The median interval from
transformation to HDT was 3 months (range, 2-20 months).
Treatment Prior to High-Dose Therapy
The characteristics and response to initial therapy prior
to HDT for all patients are summarized in Table 3. All
patients had been previously treated with chemotherapy prior
to consideration for HDT. Twelve (24%) FLGL, 4 (15%)
FLCL, and 4 (24%) TFL patients had been treated with 3 or
more different chemotherapy regimens prior to HDT. With
the exception of 3 FLGL patients who received ﬂudarabine
and 2 TFL patients who had been treated with rituximab, all
patients received chemotherapy courses of alkylator-based
multiple-agent regimens. Forty-one FLGL patients (84%)
received combination chemotherapy as part of their intitial
therapy; 19 of the 41 received cyclophosphamide, vincrisitine,
and prednisone and the remainder received various doxoru-
bicin-based regimens. The median time interval from diagno-
sis to initiation of therapy was 4 months (range, 1-110 months)
for FLGL patients. Twenty-five FLCL patients (96%)
received induction chemotherapy; the majority of them
(81%) received standard doxorubicin-containing combination
chemotherapy. Eighteen FLCL patients (70%), compared
with 29 FLGL patients (59%), achieved a first complete
remission following initial therapy. Median times to progres-
sion following initial therapy for patients with FLGL and
FLCL were 7.5 months and 11.5 months, respectively.
Approximately 1 of 5 patients had also received radio-
therapy prior to HDT. Eighteen patients received irradia-
tion as part of initial therapy, which included central nervous
system prophylaxis for 2 patients with TFL and local/
regional field irradiation in the remainder. Three FLGL
patients and 1 FLCL patient received irradiation alone as
initial therapy.
At the time of histologic transformation, salvage therapy
for the 17 TFL patients was as follows: 14 patients were
treated with combination chemotherapy, 2 received radio-
therapy alone, and 1 received rituximab. The response for
these patients included 6 (35%) complete remissions and 11
(65%) partial remissions.
Patient Characteristics at High-Dose Therapy
Characteristics of HDT and outcome are summarized in
Table 4. Twenty FLGL patients (41%) had histologic evi-
dence of marrow involvement by lymphoma at the time of
HDT; the median marrow involvement by lymphoma was
Table 2. Patient Characteristics*
FLGL FLCL TFL
(n = 49) (n = 26) (n = 17)
Age, median (range), y 48 (32-59) 51 (32-66) 47 (28-68)
Male/female, n 29/20 18/8 9/8
Stage at diagnosis, n
I/II 5 6 5
III 11 9 3
IV 33 11 9
B symptoms, n 6 2 2
Bulky mass (>10 cm), n 4 4 4
Extranodal disease, n
Marrow 34 13 8
Extramedullary 22 6 4
Diagnosis to HDT, 30 (9-178) 21.5 (7-301) 37 (8-152)
median (range),  mo
*n indicates number of patients; FLGL, follicular low-grade lym-
phoma; FLCL, follicular large cell lymphoma; TFL, transformed fol-
licular lymphoma; HDT, high-dose therapy.
Table 3. Characteristics of Pre-HDT Therapy and Response for All Patients*
FLGL FLCL TFL
(n = 49) (n = 26) (n = 17)
Number of chemotherapy 
regimens, n
1 8 7 2
2 29 15 11
≥3 12 4 4
Number of chemotherapy 
cycles, n
1-6 8 6 2
7-12 26 12 9
>12 15 6 6
Radiotherapy, n 10 6 6
Response to initial therapy, n
Complete remission 29 18 11
Partial remission 18 0 5
Progressive disease or 2 8 0
primary induction failure
Time to progression 7.5 (1-72) 11.5 (3-207) 13.2 (1-108)
following initial therapy, 
median (range),  mo
*n indicates number of patients; HDT, high-dose therapy; FLGL,
follicular low-grade lymphoma; FLCL, follicular large cell lymphoma;
TFL, transformed follicular lymphoma.
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5% (range, 5%-15%). Most FLGL patients were given HDT
in second partial remission, although 9 patients (18%) were in
second complete remission at the time of HDT. Eight FLCL
patients (31%) underwent HDT with primary induction fail-
ure as the indication. As noted above, 6 TFL patients (35%)
achieved a second complete remission after histologic trans-
formation and received HDT with that disease status, with
most of the remainder in second partial remission.
Thirty-eight FLGL and 14 FLCL patients were treated
with the FTBI-containing regimen, and the remainder
received BCNU in conjunction with etoposide and cyclo-
phosphamide. Patient characteristics according to the HDT
regimen for FLGL patients are summarized in Table 5. The
median age for FLGL patients treated with FTBI was
signiﬁcantly lower, an expected ﬁnding given the selection
criteria used for determining HDT regimen.
Treatment Outcome
There were 9 deaths (10%) during the early posttrans-
plantation period prior to day 120. Four patients died of
Table 4. HDT Characteristics and Outcome for All Patients*
FLGL FLCL TFL
(n = 49) (n = 26) (n = 17)
Marrow involvement at HDT, n 20 2 2
Disease status at HDT, n
First PR or primary 1 8 0 
induction failure
Second PR 32 9 7
Second CR 9 6 6
≥3 PR/CR 7 3 4
HDT regimen, n
FTBI/VP/CY 38 14 8
BCNU/VP/CY 11 12 9
Graft, n 
Bone marrow 19 10 7
Peripheral Blood 30 16 10
MoAb-purged 48/49 24/26 17/17
OS 4-y estimate (95% CI), % 60 (45-75) 58 (37-79) 50 (24-76)
DFS 4-y estimate (95% CI), % 44 (29-59) 51 (30-72) 49 (20-78)
*n indicates number of patients; HDT, high-dose therapy; FLGL,
follicular low-grade lymphoma; FLCL, follicular large cell lymphoma;
TFL, transformed follicular lymphoma; PR, partial remission; CR,
complete remission; FTBI, fractionated total body irradiation; VP,
etoposide; CY, cyclophosphamide; BCNU, carmustine; MoAb, mono-
clonal antibody; OS, overall survival; CI, confidence interval; DFS,
disease-free survival.
Table 5. Patient Characteristics According to HDT Regimen for FLGL
Patients*
FTBI Non-FTBI
(n = 38) (n = 11) P Value
Age, median (range), y 46 (32-59) 54 (40-58) .01†
Stage IV at diagnosis, n 27 6 .16
Pre-HDT treatment, n
≥3 Chemotherapy regimens 10 2 .28
Radiotherapy 6 4 .11
HDT disease status, n
First PR or primary 0 1 NA 
induction failure
Second PR/CR 33 8 .27
≥3 PR/CR 5 2 .32
*n indicates number of patients; HDT, high-dose therapy; FLGL,
follicular low-grade lymphoma; FTBI, fractionated total body irradia-
tion; PR, partial remission; NA, not assessed; CR, complete remission.
†Difference between FTBI and non-FTBI groups statistically
signiﬁcant (P ≤ .05).
Figure 1. Overall survival (OS) and disease-free survival (DFS) for
patients with (A) follicular low-grade lymphoma (FLGL), (B) follicular
large cell lymphoma (FLCL), and (C) transformed follicular lym-
phoma (TFL).
T.M. Cao et al.
298
diffuse alveolar hemorrhage, 2 of hepatic veno-occlusive dis-
ease, 2 of aspergillus infection, and 1 of gastrointestinal bleed-
ing due to a gastric arterio-venous malformation at day 103
post-HDT. Two additional patients experienced late deaths
while in continued remission, one at day 385 with multi-organ
failure, and the other at day 956 from bacterial sepsis.
Three patients developed secondary myelodysplasia
during the period before follow-up at 28, 30 and 64 months
after HDT. Two had received the BCNU-containing HDT
regimen. The estimated actuarial incidence for this compli-
cation was 7% at 56 months (95% CI, 0%-16%). A complex
karyotype was documented in 1 patient, which included
deletions of chromosomes 5 and 13. All 3 have died, 2 with-
out evidence of recurrent lymphoma. There were no
observed occurrences of secondary epithelial malignancies.
For the remaining 44 FLGL patients who did not
experience nonrelapse mortalities or secondary myelodys-
plasia there have been 25 relapses. Twenty-one patients
have remained alive and are in continuous remission; for
these patients the median follow-up was 45 months (range,
8-115 months). Eleven relapses were observed for the
remaining 22 FLCL patients, whereas 11 patients are alive
and, with the median follow-up of 66 months (range, 22-
134 months), are in continuous remission. For the 12 remain-
ing TFL patients there were 5 relapses, and 7 patients are
alive and in continuous remission with the median follow-up
for these patients of 64 months (range, 16-114 months).
The FLGL patients have a Kaplan-Meier estimate at
4 years for OS of 60% (95% CI, 45%-75%) and DFS of
44% (95% CI, 29%-59%). The FLCL patients have a 4-year
estimate for OS of 58% (95% CI, 37%-79%), and a DFS of
51% (95% CI, 30%-72%). The TFL patients have a 4-year
estimate for OS of 50% (95% CI, 24%-76%), and a DFS of
49% (95% CI, 20%-78%). Kaplan-Meier curves of esti-
mated survival for each group are shown in Figure 1.
Prognostic Models
Univariate analysis of potential prognostic variables by
Cox proportional hazards regression for the entire patient
group and the subset of FLGL patients is summarized in
Table 6. This analysis was not performed for the FLCL and
TFL groups because of the small sample size. The same fac-
tors were signiﬁcant correlates of OS and/or DFS for both
the entire patient group and the FLGL subset. For FLGL
patients, OS was significantly longer for patients who had
received fewer than 3 different chemotherapy regimens
(P = .003) and who were given the FTBI-containing HDT
regimen (P = .04). The FTBI HDT regimen also signifi-
cantly correlated with an improved DFS (P = .04) for FLGL
patients. Kaplan-Meier curves of OS and/or DFS rates for
Table 6. Univariate Analysis for Entire Patient Group and for FLGL Subset*
P Values for All P Values for FLGL
Patients (n = 92) Patients (n = 49)
Factor OS DFS OS DFS Favorable
Age .47 .58 .16 .72
Histology (low grade versus all patients) .70 .78 NA NA
Stage (I-III vs. IV) .17 .21 .46 .88
B symptom .75 .92 .53 .49
Bulky mass .96 .92 .65 .74
Extranodal disease (marrow) .26 .36 .73 .77
Initial therapy: no. of regimens (1-2 vs. ≥3) .003† .22 .001† .06 With <3 different regimens
Initial therapy: response (CR vs. non-CR) .80 .47 .77 .45
Initial therapy: time to progression .40 .41 .08 .23
Disease status at HDT
(CR vs non-CR) .80 .32 .82 .89
(<3 vs. ≥3 PR/CR) .54 .79 .06 .11
Marrow involvement at HDT .74 .06 .89 .06
HDT regimen (FTBI vs. non-FTBI) .04† .04† .001† .06 With FTBI-containing regimen
Graft (marrow vs. peripheral blood) .28 .50 .26 .09
*The Cox proportional hazards regression model was used to generate P values for both continuous and categorical variables as determined by
the Wald 2 test, with OS and DFS measured from the time of HDT. FLGL indicates follicular low-grade lymphoma; OS, overall survival; DFS,
disease-free survival; CR, complete remission; HDT, high-dose therapy; PR, partial remission; FTBI, fractionated total body irradiation.
†Statistically signiﬁcant (P ≤ .05).
Figure 2. Overall survival (OS) for patients with follicular low-grade
lymphoma according to the number of pre-HDT chemotherapy regi-
mens (log-rank P = .001).
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FLGL patients stratiﬁed by pre-HDT chemotherapy regi-
men number and HDT regimen are shown in Figures 2
and 3, respectively. A trend toward better DFS rates with
absence of marrow involvement at the time of HDT (P = .06)
was observed for FLGL patients but were not signiﬁcant by
univariate analysis. Results of Cox proportional hazards
multivariate regression analysis for FTBI-containing HDT
regimen, positive marrow at HDT, and number of pre-
HDT chemotherapy regimens for FLGL patients with
respect to both OS and DFS are summarized in Table 7. All
variables signiﬁcant by univariate analysis maintained signif-
icance by multivariate analysis.
The reason for a superior OS rate without an improved
DFS rate for FLGL patients who had received fewer than
3 different chemotherapy regimens prior to HDT is not
clear. However, it was observed that during the ﬁrst year fol-
lowing HDT there were 5 deaths (42%) for the group who
had been exposed to 3 or fewer chemotherapy regimens;
4 patients of this group died due to early relapse. This num-
ber is in contrast to 6 deaths (16%) among those pretreated
with fewer than 3 different regimens.
DISCUSSION
We report results with HDT and autologous transplan-
tation for relapsed FLGL that are consistent with the current
body of published data. Less heavily pretreated patients with
relapsed FLGL and those who received the FTBI-containing
HDT regimen survived longer. We also report results with
HDT for 26 patients with FLCL and 17 patients with TFL,
adding to the limited outcome data for these patients. The
Nebraska group reported on 62 FLCL patients treated with
HDT, where an estimated OS rate of 58% was observed at
5 years for those with good prognostic features [20]. Two
other groups have reviewed their experience with TFL and
had reported survival outcome similar to ours [21,22].
With the expanding number of effective treatment
options for patients with relapsed FLGL, their management
requires a balance of efficacy and treatment-related toxic-
ity. Fludarabine, targeted immunotherapy with a chimeric
anti-CD20 monoclonal antibody, and anti-CD20 radio-
immunoconjugates have all produced meaningful responses
[23-26]. Novel strategies derived from advances in basic
research such as bcl-2 antisense oligonucleotides and idio-
type vaccination may become important alternatives in the
future [27,28]. Additionally, the advent of reduced-intensity
conditioning for nonmyeloablative allogeneic hematopoietic
cell transplantation has renewed interest in inducing a
graft-versus-lymphoma effect for these patients, for whom
the mortality rates with conventional allogeneic transplanta-
tion can be prohibitive [29,30].
Although HDT and autologous transplantation for
relapsed FLGL have had consistent reports of durable
remissions in a proportion of patients, late effects including
Figure 3. Overall survival (OS) and disease-free survival (DFS) for patients with low-grade follicular lymphoma according to high-dose therapy
regimen (log-rank P = .04 for OS, and P = .04 for DFS).
Table 7. Multivariate Analysis for FLGL Patients (n = 49)*
P Values RR
OS DFS OS (95% CI) DFS (95% CI) Favorable
Initial therapy: no. of regimens (1-2 vs. ≥3) .002† .28 — 4.4 (1.8-11.2) With <3 different regimens
Marrow involvement at HDT .6 .01† — 3.1 (1.3-7.6) Without marrow involvement
HDT regimen (FTBI vs. non-FTBI) .02† .01† 3.7 (1.5-9.7) 3.0 (1.2-7.7) With FTBI-containing regimen
*Univariately signiﬁcant factors were analyzed by the Cox proportional hazards regression using a forward stepwise selection method. FLGL
indicates follicular low-grade lymphoma; RR, relative risk; OS, overall survival; DFS, disease-free survival; CI, conﬁdence interval; HDT, high-dose
therapy; FTBI, fractionated total body irradiation.
†Statistically signiﬁcant (P ≤ .05).
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secondary myelodysplasia may erode the benefit achieved
by disease control [1-9,31]. Recent studies from 2 large
centers reported an actuarial incidence for secondary
myelodysplasia that approached 20% at 10 years following
HDT [32,33]. In most of these cases, the HDT regimen
contained FTBI [34,35]. In other reports, the association
with FTBI has been questioned and the risk of secondary
myelodysplasia was primarily related to therapy received
prior to HDT [36-40].
We report both improved OS rates and DFS rates for
relapsed FLGL patients treated with FTBI in the HDT reg-
imen, although the patient numbers were small and selection
factors were used in regimen assignment. Molina et al. simi-
larly observed superior survival outcome for a FTBI-based
HDT regimen in their series of 58 patients with low-grade
follicular lymphoma [8]. Our actuarial estimate of secondary
myelodysplasia was 7% at 56 months, with 2 of 31 patients
treated in the BCNU group developing secondary myelodys-
plasia compared with 1 of 59 patients treated with FTBI.
Relapse remains the major cause of treatment failure
following HDT. Several investigators have reported
improved relapse-free survival for FLGL patients who
received transplants of purged autografts, particular those
rescued with a product that was negative for the t(14;18)
rearrangement, by the polymerase chain reaction (PCR)
[1,41]. Almost all patients (90 of 92 patients) in this study
received transplants of ex vivo “purged” hematopoietic
cells from either peripheral blood or bone marrow. Incom-
plete PCR data for the current patient group precludes
similar comparison.
The role and timing of HDT and autologous transplan-
tation must be considered in the context of the patient’s
remission status and available alternative therapies, several
of which are currently the subject of active investigation.
ACKNOWLEDGMENTS
The authors are indebted to the nurses, housestaff, fel-
lows, nurse practitioners, social workers, and case managers
of the Stanford University Medical Center for their excellent
care of our patients. The authors also thank the technolo-
gists of the Stanford University Bone Marrow Transplanta-
tion Clinical Laboratory for their competent processing of
the autografts. Special mention is made of the Bone Marrow
Transplantation data managers who have carefully worked
to document and maintain a meticulous record of the care
rendered to these patients.
REFERENCES
1. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up
of autologous bone marrow transplantation in patients with
relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
2. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A,
Armitage JO. High-dose therapy with autologous hematopoietic
rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin
Oncol. 1997;15:445-450.
3. Apostolidis J, Foran JM, Johnson PW, et al. Patterns of outcome
following recurrence after myeloablative therapy with autologous
bone marrow transplantation for follicular lymphoma. J Clin
Oncol. 1999;17:216-221.
4. Colombat P, Donadio D, Fouillard L, et al. Value of autologous
bone marrow transplantation in follicular lymphoma: a France
Autogreffe retrospective study of 42 patients. Bone Marrow Trans-
plant. 1994;13:157-162.
5. Lopez R, Martino R, Sureda A, et al. Autologous stem cell trans-
plantation in advanced follicular lymphoma. A single center expe-
rience. Haematologica. 1999;84:350-355.
6. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative ther-
apy with autologous bone marrow transplantation as consolida-
tion therapy for recurrent follicular lymphoma. J Clin Oncol.
1994;12:1177-1184.
7. Haas R, Moos M, Mohle R, et al. High-dose therapy with periph-
eral blood progenitor cell transplantation in low-grade non-
Hodgkin’s lymphoma. Bone Marrow Transplant. 1996;17:149-155.
8. Molina A, Nademanee A, O’Donnell MR, et al. Long-term fol-
low-up and analysis of prognostic factors after high-dose therapy
(HDT) and peripheral blood stem cell autografting (ASCT) in
58 patients (PTS) with a history of low grade follicular lymphoma
(FLGL) [abstract]. Blood. 1999;94(suppl):747.
9. Golden J, Gooley T, Gopal A, et al. Allogeneic (ALLO) or autol-
ogous (AUTO) bone marrow (BM)/peripheral blood stem cell
(PBSC) transplantation for follicular lymphoma (FL): a cohort
analysis from the Fred Hutchinson Cancer Research [abstract].
Blood. 1999;94(suppl):717.
10. National Cancer Institute sponsored study of classiﬁcations of non-
Hodgkin’s lymphomas: summary and description of a working for-
mulation for clinical usage. The Non-Hodgkin’s Lymphoma
Pathologic Classiﬁcation Project. Cancer. 1982;49:2112-2135.
11. Horning SJ, Weiss LM, Nevitt JB, Warnke RA. Clinical and
pathologic features of follicular large cell (nodular histiocytic)
lymphoma. Cancer. 1987;59:1470-1474.
12. Jin NR, Hill RS, Petersen FB, et al. Marrow harvesting for autol-
ogous marrow transplantation. Exp Hematol. 1985;13:879-884.
13. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of
enriched and purged peripheral blood progenitor cells from a sin-
gle apheresis product in patients with non-Hodgkin’s lymphoma.
Blood. 1995;85:3334-3341.
14. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Inﬂuence
of preparatory regimen and source of hematopoietic cells on out-
come of autotransplantation for non-Hodgkin’s lymphoma. Biol
Blood Marrow Transplant. 1996;2:76-85.
15. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable
treatment outcome in non-Hodgkin’s lymphoma patients with
“poor” mobilization of peripheral blood progenitor cells. Biol
Blood Marrow Transplant. 2000;6:506-512.
16. Cox DR. Regression models and life tables. J R Stat Soc.
1972;34:187-220.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
18. Mantel M. Evaluation of survival data and two new rank order
statistics arising in its consideration. Cancer Chemother Rep.
1966;50:163-170.
19. Armitage P. Statistical Methods in Medical Research. London, Eng-
land: Blackwell Scientiﬁc; 1971.
20. Vose JM, Bierman PJ, Lynch JC, et al. Effect of follicularity on
autologous transplantation for large-cell non-Hodgkin’s lym-
phoma. J Clin Oncol. 1998;16:844-849.
21. Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone
marrow transplantation after histologic transformation of indo-
lent B cell malignancies. Biol Blood Marrow Transplant. 1999;5:
262-268.
HDT and Autografting in Follicular Lymphoma
301B B & M T
22. Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy
with autologous haematopoietic support in patients with trans-
formed follicular lymphoma: a study of 27 patients from a single
centre. Ann Oncol. 1998;9:865-869.
23. Hochster HS, Kim KM, Green MD, et al. Activity of ﬂudarabine
in previously treated non-Hodgkin’s low-grade lymphoma: results
of an Eastern Cooperative Oncology Group study. J Clin Oncol.
1992;10:28-32.
24. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludara-
bine, mitoxantrone, and dexamethasone: an effective new regimen
for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
25. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab
chimeric anti-CD20 monoclonal antibody therapy for relapsed
indolent lymphoma: half of patients respond to a four-dose treat-
ment program. J Clin Oncol. 1998;16:2825-2833.
26. Kaminski M, Zelenetz AD, Press O. Multicenter, phase III study
of Iodine-131 tositumomab (Anti-B1 Antibody) for chemo-
therapy-refractory low-grade or transformed low grade non-
Hodgkin’s lymphoma [abstract]. Blood Supplement. 1998;92:1296.
27. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-speciﬁc idiotype
vaccines in the treatment of patients with B-cell lymphoma—
long-term results of a clinical trial. Blood. 1997;89:3129-3135.
28. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and
pharmacokinetic study of bcl-2 antisense oligonucleotide therapy
in patients with non-Hodgkin’s lymphoma [see comments]. J Clin
Oncol. 2000;18:1812-1823.
29. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induc-
tion of graft-versus-malignancy using ﬂudarabine-based nonablative
chemotherapy and allogeneic blood progenitor-cell transplanta-
tion as treatment for lymphoid malignancies. J Clin Oncol. 1998;
16:2817-2824.
30. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone
marrow transplantation for low-grade lymphoma. Blood. 1998;92:
1832-1836.
31. Schouten IC, Raemaekers JJ, Kluin-Nelemans HC, van Kamp H,
Mellink WA, van’t Veer MB. High-dose therapy followed by bone
marrow transplantation for relapsed follicular non-Hodgkin’s lym-
phoma. Dutch HOVON Group. Ann Hematol. 1996;73:273-277.
32. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients
with myelodysplastic syndrome after autologous bone marrow
transplantation for non-Hodgkin’s lymphoma. J Clin Oncol.
1999;17:3128-3135.
33. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-
related myelodysplasia and secondary acute myelogenous
leukemia after high-dose therapy with autologous hematopoietic
progenitor-cell support for lymphoid malignancies. J Clin Oncol.
2000;18:947-955.
34. Darrington DL, Vose JM, Anderson JR, et al. Incidence and char-
acterization of secondary myelodysplastic syndrome and acute
myelogenous leukemia following high-dose chemoradiotherapy
and autologous stem-cell transplantation for lymphoid malignan-
cies. J Clin Oncol. 1994;12:2527-2534.
35. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary
leukaemia and myelodysplasia after autografting for lymphoma:
results from the EBMT. EBMT Lymphoma and Late Effects
Working Parties. European Group for Blood and Marrow Trans-
plantation. Br J Haematol. 1999;106:1020-1026.
36. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC,
Forman SJ. Clonal karyotypic hematopoietic cell abnormalities
occurring after autologous bone marrow transplantation for
Hodgkin’s disease and non- Hodgkin’s lymphoma. Blood. 1994;84:
957-963.
37. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-
related leukemia and myelodysplasia following autologous trans-
plantation for lymphoma: an assessment of risk factors. Blood.
2000;95:1588-1593.
38. Park S, Brice P, Noguerra ME, et al. Myelodysplasias and
leukemias after autologous stem cell transplantation for lymphoid
malignancies. Bone Marrow Transplant. 2000;26:321-326.
39. Del Canizo M, Amigo M, Hernandez JM, et al. Incidence and
characterization of secondary myelodysplastic syndromes follow-
ing autologous transplantation. Haematologica. 2000;85:403-409.
40. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard
therapy is the likely cause of MDS after autotransplants for multi-
ple myeloma. Br J Haematol. 1996;95:349-353.
41. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone
marrow in autologous bone marrow transplantation for non-
Hodgkin’s lymphoma: a case-matched comparison with unpurged
cases by the European Blood and Marrow Transplant Lymphoma
Registry. J Clin Oncol. 1996;14:2454-2464.
